They further designed a novel nanodelivery vehicle (T-siHER2-NP(DTX)) for the treatment of HER2+ breast cancer, namely a combination of taxane and HER2-targeting antibodies [77]. The gene discussed is ERBB2; the disease is breast carcinoma.